News
New scientific paper about hypoallergenic variants of horse allergen Equ c 1
The latest open access paper about our hypoallergen development is available at Nature Scientific Reports. The paper,...
Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments
Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve...
Desentum aims to initiate clinical trials with its birch pollen allergy vaccine this fall
Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead...
Desentum wins a 1.9 M€ EU grant for first-in-human clinical trials
Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The...
Syys-lokakuussa on mahdollisuus sijoittaa Desentumiin
Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä...
Desentum raises EUR 2.3 million to test allergy vaccine
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen...
Desentum is preparing to start clinical trials with birch pollen allergy vaccine
Desentum is approaching first-in-man clinical trials with its lead product candidate, a modified hypoallergen aimed...
Desentum has two presentations in EAACI 2017
The annual congress of the European Academy of Allergy and Clinical Immunology will be in Helsinki in June 17-21....
Desentum closes financial round totalling nearly EUR 2 million
Desentum secured funding to advance their treatment targeting birch pollen allergy. ESPOO, Finland, 23 January...